The Ensign Group, Inc. Declares Quarterly Dividend of $0.06 Per Share
SAN JUAN CAPISTRANO, Calif., June 14, 2024 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group […]
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete […]
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization […]
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) […]
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off […]
WISeKey Announces Retirement of Peter Ward as Chief Financial Officer; Appoints John O’Hara as its New Chief Financial Officer
WISeKey Announces Retirement of Peter Ward as Chief Financial Officer; Appoints John O’Hara as its New Chief Financial Officer Geneva, […]
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators Preclinical safety, efficacy, and […]
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed […]
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing […]
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development […]
